AsianScientist (Nov. 65, 2013) – Merck has invested €80 million into a new pharmaceutical manufacturing facility, to be located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region, China.
“This further investment in China reflects Merck’s long-term commitment to the country where our group has been present for 80 years,” said Belén Garijo, CEO of Merck Serono, the biopharmaceutical division of Merck.
“We are proud to be one of the first multinational companies investing in a local site focused on the manufacturing of medicines referenced in China’s essential drug list, and serve the country’s expanding healthcare needs in the areas of diabetes, cardiovascular diseases and thyroid disorders, by bringing high-quality medicines made in China to a broader population, in full alignment with the Chinese government’s goal to increase access to quality products.”
The new facility will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck’s brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders respectively.
Located in NETDA’s BioSpark, an industrial park designed to accommodate the life science industry, the new facility will cover an area of 40,000 square meters, with a possible 20,000 square meters extension.
“This new facility will become Merck Serono’s second largest pharmaceutical manufacturing site in the world and will help ensure that our medicines will always be available to patients who rely on them, which is a key priority for Merck Serono,” said Allan Gabor, director of Merck Serono in China.
“With our research center, our development capabilities, our commercial presence and this new manufacturing facility, we are building for the future in China by investing across our value chain.”
——
Source: Merck Group.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
